Early rituximab treatment reduces long-term disability in aquaporin-4 antibody-positive neuromyelitis optica spectrumSu Yeon Park, Eun Hee Sohn, Kyong Jin Shin et al.|Journal of Neurology Neurosurgery & Psychiatry|2023Cited by 18
Comparison of MOG and AQP4 antibody seroprevalence in Korean adults with inflammatory demyelinating CNS diseasesJae‐Won Hyun, Ho Jin Kim, Hye Lim Lee et al.|Multiple Sclerosis Journal|2020Cited by 14
Evaluating Rituximab Failure Rates in Neuromyelitis Optica Spectrum Disorder: A Nationwide Real-World Study From South KoreaSu‐Hyun Kim, Ho Jin Kim, Ju‐Hong Min et al.|Journal of Clinical Neurology|2025Cited by 11
Safety and Temporal Pattern of the Lymphocyte Count During Fingolimod Therapy in Patients With Multiple Sclerosis: Real-World Korean ExperienceSo‐Young Huh, Ho Jin Kim, Su‐Hyun Kim et al.|Journal of Clinical Neurology|2022Cited by 5
Outcomes of immunosuppressive therapy discontinuation in patients with myelin oligodendrocyte glycoprotein antibody-associated diseaseYou‐Ri Kang, Hyunjin Ju, Ki Hoon Kim et al.|Multiple Sclerosis Journal|2025Cited by 5